Essential oil composition for preventing or / and treating upper respiratory tract infection or rhinitis and application

Abstract

The invention provides application of combined use of radix saposhnikoviae essential oil and rhizoma atractylodis macrocephalae essential oil in preparation of a medicine for preventing or / and treating upper respiratory tract infection or rhinitis. The invention also provides an essential oil composition for preventing or / and treating upper respiratory tract infection or rhinitis. The essential oil extract raw material combination can regulate qi and blood and viscera functions of the whole body to enhance the resistance of the body and promote the discharge of pathogenic qi, and has multiple effects of resisting viruses, resisting bacteria, enhancing immunity and the like. The traditional Chinese medicine emphasizes that healthy qi is stored in the interior and pathogens cannot be dried, and the essential oil extract pays attention to improvement of the overall defense function of the upper respiratory tract, enhancement of the spreading and descending functions of lung qi, regulation of the transportation and transformation functions of the spleen and the stomach and the like so as to improve the resistance of the organism to external pathogens.

Description

TECHNICAL FIELD

[0001] The present application relates to a kind of essential oil composition for preventing or / and treating upper respiratory tract infection or rhinitis. BACKGROUND

[0002] Upper respiratory tract infection (URTI) generally refers to inflammation including nasal cavity, pharynx, throat, is caused by a variety of microorganisms including bacteria and viruses, a common respiratory disease, 70% to 80% of common pathogen of URTI is virus, in addition, bacterial infection accounts for about 20% to 30%. According to epidemiological investigation shows that children less than 5 years old are statistically average per person per year suffers from URTI 4-6 times, the incidence of URTI is high, and repeatedly attacks, causes serious harm to patients and society.

[0003] As one of the diseases of upper respiratory tract infection-rhinitis is one of the six chronic diseases of WHO in the 21st century, the prevalence rate shows a rising trend year by year. Rhinitis not only seriously affects the quality of life and mental health of patients, and its high prevalence also brings considerable medical burden to rhinitis patients and society. Rhinitis has become a serious public health problem that threatens human health.

[0004] At present, there is no specific method for URTI in western medicine, mainly symptomatic treatment, can use oseltamivir, ribavirin and other antiviral drugs, penicillin, cephalosporin, macrolide drugs and other antibiotics for antiviral, antibacterial treatment. Antiviral drugs can shorten the course of disease, reduce symptoms, and need to be used in early infection. But long-term use of western medicine is easy to lead to drug resistance, for repeated upper respiratory tract infection, the role of intrinsic factors in the human body is more and more obvious, some new clinical features appear, and the effect of simple use of western medicine is not ideal for some patients. And for rhinitis, nasal preparations are still the main choice for treatment, among which, nasal hormones are recommended as first-line drugs, other drugs including antihistamines, antileukotriene drugs, etc., although they can control symptoms, but often difficult to meet the needs of patients, and often accompanied by nasal burning, dryness, tingling, nosebleed, pharyngitis, drowsiness and cough and other adverse reactions, and the degree and incidence of adverse reactions may increase when used for a long time.

[0005] In addition, due to different causes, the classification of rhinitis is also complex, such as allergic rhinitis (allergic rhinitis), infectious rhinitis, drug-induced rhinitis, occupational rhinitis, atrophic rhinitis, etc., the clinical treatment methods are different for different causes.

[0006] Traditional Chinese Medicine (TCM) classifies URTIs as "colds," "febrile diseases," or "exogenous febrile diseases." They are caused by the six exogenous pathogens (wind, cold, heat, dampness, dryness, and fire) or seasonal epidemics. Wind, the root of all diseases, often combines with other pathogenic qi to cause disease, attacking the lung's defenses, leading to disharmony between the defenses and the surface, and a failure of the lungs to clear and purify themselves. Dispersing wind-heat and clearing heat and detoxifying are the most commonly used treatments. Rhinitis, which falls under the TCM category of "nasal allergies," is a lung disease. The lung's orifice is the nose, and if the lung's defenses are not strong, invasion by wind, cold, or other pathogenic qi binds the muscles and surfaces, preventing the release of yang qi, resulting in the upward release of sneezes. The "Ben Shen Pian" in the "Ling Shu" states, "Lung qi deficiency leads to nasal congestion, poor circulation, and decreased energy."

[0007] Application number 202311469015.8, invention title: A Traditional Chinese Medicine Composition for Preventing and Treating Rhinitis, Preparation Method, and Use Thereof. The Traditional Chinese Medicine Composition for Preventing and Treating Rhinitis of the present invention is prepared from the following raw materials: magnolia essential oil, lavender essential oil, Australian tea tree essential oil, orange blossom essential oil, garlic essential oil, peppermint essential oil, astragalus essential oil, siler essential oil, atractylodes essential oil, schizonepeta macrocephala essential oil, ginger essential oil, asarum essential oil, saffron essential oil, eucalyptus essential oil, schizonepeta essential oil, and a base oil. Traditional Chinese Medicine emphasizes holistic thinking and syndrome differentiation and treatment. The human body is an organic whole, and diseases are interconnected. In addition to nasal symptoms, upper respiratory tract infections may also be accompanied by systemic symptoms such as fever, fatigue, and headache. The prescription disclosed in this patent document has a narrow scope of application, limited ability to regulate systemic symptoms, difficulty in coping with complex changes in the disease, and lacks improvement in the overall defense function of the upper respiratory tract. It focuses on relieving local symptoms of the nose, such as nasal congestion, runny nose, sneezing, etc., has a narrow scope of application, and has a relatively weak effect on regulating systemic symptoms, and has an even smaller effect on improving the overall defense function of the upper respiratory tract. Summary of the Invention

[0008] The present invention provides an essential oil composition for preventing and / or treating upper respiratory tract infection or rhinitis.

[0009] The present invention provides a use of fangfeng essential oil and atractylodes macrocephala essential oil in combination for preparing a medicament for preventing and / or treating upper respiratory tract infection or rhinitis, wherein the weight ratio of fangfeng essential oil and atractylodes macrocephala essential oil is:

[0010] 0.5-1.5 parts of siler essential oil and 0.5-1.5 parts of atractylodes macrocephala essential oil;

[0011] Preferably, the weight ratio of siler essential oil and atractylodes macrocephala essential oil is:

[0012] 1 part of fangfeng essential oil and 1 part of atractylodes essential oil.

[0013] Preferably, the drug is a drug for preventing or / treating allergic rhinitis.

[0014] The present invention also provides an essential oil composition for preventing and / or treating upper respiratory tract infection or rhinitis, which is composed of the following raw materials in the following weight ratios:

[0015] 0.5-1.5 parts of the essential oil of Saposhnikovia divaricata, 0.5-1.5 parts of the essential oil of Atractylodes macrocephala;

[0016] Preferably, the raw materials are composed of the following weight ratio:

[0017] 1 part of the essential oil of Saposhnikovia divaricata, 1 part of the essential oil of Atractylodes macrocephala.

[0018] The raw materials further comprise the essential oil of Atractylodes lancea, and the weight ratio of the raw materials is:

[0019] 0.5-1.5 parts of the essential oil of Saposhnikovia divaricata, 0.5-1.5 parts of the essential oil of Atractylodes macrocephala, 0.5-1.5 parts of the essential oil of Atractylodes lancea;

[0020] Preferably, the weight ratio of the raw materials is: 1 part of the essential oil of Saposhnikovia divaricata, 1 part of the essential oil of Atractylodes macrocephala, 1 part of the essential oil of Atractylodes lancea.

[0021] The raw materials further comprise the essential oil of Magnolia biondii, the essential oil of Mentha haplocalyx, and the essential oil of Perilla frutescens, and the weight ratio of the raw materials is: 0.5-1.5 parts of the essential oil of Saposhnikovia divaricata, 0.5-1.5 parts of the essential oil of Atractylodes macrocephala, 0.5-1.5 parts of the essential oil of Atractylodes lancea, 1-3 parts of the essential oil of Magnolia biondii, 1-3 parts of the essential oil of Mentha haplocalyx, and 0.5-1.5 parts of the essential oil of Perilla frutescens;

[0022] Preferably, the weight ratio of the raw materials is: 1 part of the essential oil of Saposhnikovia divaricata, 1 part of the essential oil of Atractylodes macrocephala, 1 part of the essential oil of Atractylodes lancea, 2 parts of the essential oil of Magnolia biondii, 2 parts of the essential oil of Mentha haplocalyx, and 1 part of the essential oil of Perilla frutescens.

[0023] The raw materials further comprise the essential oil of Eucalyptus globulus or the essential oil of Kirengeshoma palmata or the essential oil of Cinnamomum oleiferum or the essential oil of Cymbopogon citratus, and the weight ratio of the raw materials is: 0.5-1.5 parts of the essential oil of Saposhnikovia divaricata, 0.5-1.5 parts of the essential oil of Atractylodes macrocephala, 0.5-1.5 parts of the essential oil of Atractylodes lancea, 1-3 parts of the essential oil of Magnolia biondii, 1-3 parts of the essential oil of Mentha haplocalyx, 0.5-1.5 parts of the essential oil of Perilla frutescens, and 0.5-3 parts of the essential oil of Eucalyptus globulus or the essential oil of Kirengeshoma palmata or the essential oil of Cinnamomum oleiferum or the essential oil of Cymbopogon citratus;

[0024] Preferably, the weight ratio of the raw materials is: 1 part of the essential oil of Saposhnikovia divaricata, 1 part of the essential oil of Atractylodes macrocephala, 1 part of the essential oil of Atractylodes lancea, 2 parts of the essential oil of Magnolia biondii, 2 parts of the essential oil of Mentha haplocalyx, 1 part of the essential oil of Perilla frutescens, and 2 parts of the essential oil of Eucalyptus globulus.

[0025] The raw materials further comprise the essential oil of Citrus aurantium, the essential oil of Jasminum grandiflorum, the essential oil of Rosa rugosa, and the essential oil of Ylang-ylang.

[0026] The application further provides the use of the essential oil composition in the preparation of an external medicine or preparation for preventing or / and treating upper respiratory tract infection or rhinitis.

[0027] The rhinitis is allergic rhinitis.

[0028] The preparation of the external use medicine is inhalant, atomization agent, acupoint administration agent.

[0029] Preferably, the acupoint administration agent is administered at the temple, the Xingxi acupoint, the Fengchi acupoint and the Quchi acupoint.

[0030] The prescription is mainly used for upper respiratory tract infection with wind-cold syndrome and rhinitis with wind-cold and dampness. The wind-cold evil invades the human body, the defensive yang is blocked, the pores are closed, the lung qi is not released, thus the symptoms of upper respiratory tract infection such as cold, fever, headache, body pain, nasal congestion, runny nose and cough occur. The body's weifang function is insufficient, the wind-cold evil invades the skin, and the lung is the first to be affected. The lung opens in the nose, the wind-cold evil invades the lung, the lung qi is not released, and the nasal cavity is not smooth, thus the symptoms of rhinitis such as nasal congestion, clear runny nose and sneezing occur. If the patient has a weak spleen, or is affected by the wind-cold evil after the spleen and stomach function, water and dampness are retained, and the performance of dampness such as heavy limbs, chest tightness, poor appetite and the like also occurs. The ancient name of Ledebouriella is'screen', which means that it can resist the wind like a screen. It tastes bitter and sweet, and is slightly warm and moist, and is a'moistening agent in wind medicine'. Ledebouriella can treat both external and internal wind, so it is called 'wind medicine', and has the effects of dispelling wind and relieving superficies, overcoming dampness and relieving pain, and stopping convulsion. Atractylodes is called 'the first important medicine for tonifying qi and invigorating the spleen', and is known as 'North Ginseng and South Atractylodes', and has the effects of tonifying qi and invigorating the spleen, drying dampness and water, stopping sweating, and preventing miscarriage. Ledebouriella and Atractylodes are combined, which can lead Atractylodes into the spleen and stomach meridian, and Ledebouriella can relax the spleen to help Atractylodes tonify the earth, so that the spleen earth can overcome dampness; Atractylodes is warm and sweet, and is good at tonifying the spleen and yang, and tonifying the spleen qi and invigorating the spleen yang. The combination of the two can achieve the effect of invigorating the spleen and tonifying qi and overcoming dampness, which can dispel wind evil and not hurt the skin due to the loosening of the pores, and the two drugs are the monarch drugs. Atractylodes is a pungent herb that enters the spleen, and is used with Atractylodes and Ledebouriella to enhance the effect of invigorating the spleen and drying dampness, dispelling wind and dispelling cold, and is a ministerial drug. Magnolia disperses wind and cold, and opens the nasal cavity; Perilla relieves superficies and dispels cold, and regulates qi and stomach, and is used with Ledebouriella to dispel wind and relieve superficies, and dispel the wind-cold evil in the nasal cavity; Mint clears the head and eyes, and is used with Magnolia to improve the symptoms of nasal congestion and runny nose, and the three drugs are the auxiliary drugs. Eucalyptus releases the lung and stops coughing, dispels wind and cold, clears heat and resolves toxicity, and regulates blood and qi, and is used with Ledebouriella and Perilla to enhance the effect of dispelling wind and cold, and is used with Mint to improve the symptoms of nasal congestion and runny nose, and is an assistant drug to help other drugs to improve the state of blood stasis in the nasal cavity, and is a ministerial drug.

[0031] The raw material combination of the essential oil extract of the application adjusts the functions of the whole body qi and blood and viscera, enhances the resistance of the body, promotes the discharge of evil qi, and has multiple effects such as antiviral, antibacterial and enhancing immunity. Traditional Chinese medicine emphasizes that 'the healthy qi is stored in the body, and the evil cannot intrude', and the essential oil extract of the application focuses on improving the overall defense function of the upper respiratory tract, enhancing the releasing and descending function of lung qi, regulating the transportation and transformation function of the spleen and stomach, and improving the resistance of the body to external evil qi. DETAILED DESCRIPTION

[0032] Example 1 Preparation of the compound essential oil of the application

[0033] Example 1: Fangfeng essential oil 0.5g, Baizhu essential oil 1.5g

[0034] Example 2: Fangfeng essential oil 1g, Baizhu essential oil 1g

[0035] Example 3: Fangfeng essential oil 1.5g, Baizhu essential oil 0.5g

[0036] Example 4: Fangfeng essential oil 0.5g, Baizhu essential oil 1.5g, Changzhu essential oil 1.5g

[0037] Example 5: Fangfeng essential oil 1g, Baizhu essential oil 1g, Changzhu essential oil 1g

[0038] Example 6: Fangfeng essential oil 1.5g, Baizhu essential oil 0.5g, Changzhu essential oil 0.5g

[0039] Example 7: Fangfeng essential oil 0.5g, Baizhu essential oil 1.5g, Changzhu essential oil 1.5g, Xinyi essential oil 1g, Bohe essential oil 1g, Zhusu essential oil 1.5g

[0040] Example 8: Fangfeng essential oil 1g, Baizhu essential oil 1g, Changzhu essential oil 1g, Xinyi essential oil 2g, Bohe essential oil 2g, Zhusu essential oil 1g

[0041] Example 9: Fangfeng essential oil 1.5g, Baizhu essential oil 0.5g, Changzhu essential oil 0.5g, Xinyi essential oil 3g, Bohe essential oil 3g, Zhusu essential oil 0.5g

[0042] Example 10: Fangfeng essential oil 0.5g, Baizhu essential oil 1.5g, Changzhu essential oil 1.5g, Xinyi essential oil 1g, Bohe essential oil 1g, Zhusu essential oil 1.5g, Yujiali (Eucalyptus leaf) essential oil 3g.

[0043] Example 11: Fangfeng essential oil 1g, Baizhu essential oil 1g, Changzhu essential oil 1g, Xinyi essential oil 2g, Bohe essential oil 2g, Zhusu essential oil 1g, Yujiali (Eucalyptus leaf) essential oil 2g.

[0044] Example 12: Fangfeng essential oil 1.5g, Baizhu essential oil 0.5g, Changzhu essential oil 0.5g, Xinyi essential oil 3g, Bohe essential oil 3g, Zhusu essential oil 0.5g, Yujiali (Eucalyptus leaf) essential oil 1g.

[0045] In the preparation of compound essential oil, the amount of each component needs to be comprehensively considered the efficacy after compounding, as well as the odor, properties, safety and irritation of the essential oil after compounding. The efficacy of the pre-experiment was used to screen the compounding ratio of different essential oils. The results showed that the compound essential oils could obviously inhibit the bacteria related to upper respiratory tract infection, and the antibacterial activity of Example 10 was the strongest; the compound essential oils could obviously inhibit the viruses related to upper respiratory tract infection, and the antiviral activity of Examples 10 and 11 was relatively strong; the compound essential oils could significantly enhance the phagocytosis function of liver and spleen macrophages in immunosuppressed mice, and the efficacy of Example 11 was the most significant. The compound essential oils could obviously improve the symptoms of guinea pig rhinitis, and Example 11 was the best, and the odor acceptance of Example 11 was the best.

[0046] The beneficial effects of the present application are proved by the pharmacodynamic test and clinical test.

[0047] Test Example 1 In vitro antibacterial and antiviral activity related to respiratory tract infection

[0048] 1. Antibacterial activity

[0049] 1.1 Test substance

[0050] Compound essential oil group 1: 1g of fangfeng essential oil and 1g of baizhu essential oil.

[0051] Compound essential oil group 2: 1g of fangfeng essential oil, 1g of baizhu essential oil and 1g of cangzhu essential oil.

[0052] Compound essential oil group 3: 1g of fangfeng essential oil, 1g of baizhu essential oil, 1g of cangzhu essential oil, 2g of xinyi essential oil, 2g of bohe essential oil and 1g of zhusu essential oil.

[0053] Compound essential oil group 4: 1g of fangfeng essential oil, 1g of baizhu essential oil, 1g of cangzhu essential oil, 2g of xinyi essential oil, 2g of bohe essential oil, 1g of zhusu essential oil and 2g of youjiali (eucalyptus leaf) essential oil.

[0054] 1.2 Preparation of culture medium

[0055] MH: According to the instructions, mix the MH agar dry powder with ddH2O in proportion, adjust the pH to 7.2-7.3. After treatment by high-pressure sterilization pot, when the solution cools to 45℃, pour it into a 90mm diameter flat plate culture dish, 20mL per dish. After standing for 24 hours, the culture dish can be used for experiment.

[0056] MHF: According to the instructions, mix the MH agar dry powder with ddH2O in proportion, and adjust the pH to 7.2-7.3. After high-pressure sterilization, when the solution cools down, add 5% sterile defibrillated horse blood and 20mg / L β-NAD, mix thoroughly. Pour the mixed solution into a 90mm diameter flat plate culture dish, 20mL per dish. After standing for 24 hours, the culture dish can be used for experiment.

[0057] 1.3 Preparation of essential oil emulsion

[0058] 1 mL Tween 80 was measured and added to 99 mL of normal saline to obtain a 1% Tween 80 solution; 1 g of essential oil was added to 1% Tween 80 solution and diluted to 100 mL to obtain an essential oil emulsion of 10 mg / mL (the same dosage was used in each experimental group).

[0059] 1.4 Measurement of inhibition zone size

[0060] An appropriate amount of S. aureus was used to perform partition streak inoculation on MH plates using a sterile inoculation loop. The inoculated agar plates were then placed in an incubator at 37°C for 24 hours to activate the strain. An appropriate amount of S. pneumoniae, H. influenzae, and S. pyogenes was used to inoculate MHF plates using a sterile inoculation loop. The inoculated plates were then placed in an incubator at 37°C for 24 hours to activate the strain. The four bacteria were diluted with sterile normal saline to obtain a bacterial suspension, and the solution was shaken to obtain a bacterial concentration of about 10 6 CFU / mL. The filter paper disc method was used to measure the inhibition zone size. 150 μl of the bacterial solution was taken using a sterile pipette and added dropwise to the MH or MHF medium, which was then evenly spread. After spreading, three 6 mm sterile round filter paper discs were placed equidistantly on each bacterial plate, and 10 μl of 10 mg / mL ceftazidime (positive control), 10 mg / mL essential oil emulsion, and 1% Tween 80 solution (blank group) were added dropwise. Each bacterial species was measured in triplicate. After 24 hours of incubation at 37°C, the diameters of the inhibition zones were measured using a cross method, and the antibacterial effects were compared.

[0061] 1.5 Results and conclusions

[0062] The diameters of the inhibition zones of ceftazidime, essential oil of Atractylodes macrocephala Koidz, essential oil of Saposhnikovia divaricata, and compound essential oils 1-4 on the four bacteria are shown in Table 1. Compared with the blank group, ceftazidime and the essential oil groups had significant inhibitory activity on S. aureus, S. pneumoniae, H. influenzae, and S. pyogenes (P<0.01). Compared with the ceftazidime group, compound essential oils 3-4 had no significant difference in inhibitory activity on S. aureus, and compound essential oil 4 had no significant difference in inhibitory activity on S. pneumoniae and S. pyogenes. Essential oil of Atractylodes macrocephala Koidz and essential oil of Saposhnikovia divaricata had certain inhibitory activity on S. aureus, S. pneumoniae, H. influenzae, and S. pyogenes. Different formulations of compound essential oils had different antibacterial effects on the four bacteria, and some compound essential oil groups showed stronger antibacterial effects. Compound essential oil 4 had stronger inhibitory activity on S. aureus, S. pneumoniae, and S. pyogenes than ceftazidime.

[0063] Table 1 Diameter of inhibition zone (mm)

[0064]

[0065] Note: compared with the blank group, * P<0.05, ** P<0.01; compared with the ceftazidime group, # P<0.05, ## P<0.01;

[0066] 2 Antiviral activity

[0067] 2.1 Test substances

[0068] Compound essential oil group 1: 1 g of essential oil of Fangfeng, 1 g of essential oil of Baizhu.

[0069] Compound essential oil group 2: 1 g of essential oil of Fangfeng, 1 g of essential oil of Baizhu, 1 g of essential oil of Cangzhu.

[0070] Compound essential oil group 3: 1 g of essential oil of Fangfeng, 1 g of essential oil of Baizhu, 1 g of essential oil of Cangzhu, 2 g of essential oil of Xinyi, 2 g of essential oil of Bohe, 1 g of essential oil of Zixu.

[0071] Compound essential oil group 4: 1 g of essential oil of Fangfeng, 1 g of essential oil of Baizhu, 1 g of essential oil of Cangzhu, 2 g of essential oil of Xinyi, 2 g of essential oil of Bohe, 1 g of essential oil of Zixu, 2 g of essential oil of Youjiali (eucalyptus leaf).

[0072] 2.2 Cell culture

[0073] Dog kidney cells (MDCK), human laryngeal epidermoid carcinoma cells (HEP-2), and HEL cells were cultured in DMEM medium containing 10% FBS in a 37℃, 5% CO2 incubator, and subcultured every 3 days.

[0074] 2.3 Virus amplification

[0075] Influenza A virus and influenza B virus were inoculated on MDCK cells that had grown into a monolayer, RSV was inoculated on HEP-2 cells that had grown into a monolayer, and rhinovirus was inoculated on HEL cells that had grown into a monolayer. 2% 1640 maintenance solution was added, and the cells were incubated at 37℃ in a 5% CO2 environment. After more than 90% of the lesions appeared, the cells were removed, subjected to repeated freeze-thawing 3 times, centrifuged at 1000 r / min by a blowing centrifuge for 10 min, and the supernatant was quantitatively subpackaged and stored in a –80℃ refrigerator for standby use.

[0076] 2.4 Virus virulence determination

[0077] Cells in the logarithmic growth phase were digested and adjusted to 1×10 5 / mL, 100 μL of each dilution was inoculated into 96-well plates, 24 h later, the culture solution was removed, 100 μL of the virus to be tested was added in a 10-fold serial dilution, 4 wells were repeated for each concentration, and a cell control was set. Culturing in a 37°C, 5% CO2 incubator, observing under an inverted microscope for 24 h, adding 10 μL of MTT staining solution with a mass concentration of 5 mg / mL to each well, culturing in a 37°C, 5% CO2 incubator for 4 h, then removing the staining solution, adding 100 μL of DMSO solution, decolorizing at room temperature for 10 min, and measuring the OD value at 490 nm by using an enzyme-labeled instrument. The median infectious concentration TCID50 of the virus solution was calculated according to the Reed-Muench formula 50 .

[0078] 2.5 Antiviral effect of essential oil

[0079] Well-grown MDCK cells, HEP-2 cells and HEL cells were inoculated into 97-well plates, and cultured in a 37°C, 5% CO2 incubator for 24 h, then the supernatant was removed, 100 μL of a mixture of essential oil diluted to 10 μg / mL with 2% 1640 maintenance solution and an equal volume of 100 TCID 50 50 μL of virus and 50 μL of cell maintenance solution was added to the virus control group, and 50 μL of 10 μg / mL ribavirin and 50 μL of virus was added to the ribavirin group. The 96-well plate was placed in a 37°C, 5% CO2 incubator for culturing, and the cytopathic effect was observed every day. When more than 75% of the cells showed cytopathic effect, it was 4+, 50-75% of the cells showed cytopathic effect, it was 3+, 25-50% of the cells showed cytopathic effect, it was 2+, less than 25% of the cells showed cytopathic effect, it was +, and no cytopathic effect was -. When the cytopathic effect (CPE) of the virus control group reached 4+, the experiment was terminated.

[0080] 2.6 Results and conclusion

[0081] The cell pathogenic effect of ribavirin, atractylodes lancea essential oil, saposhnikovia divaricata essential oil, and compound essential oils 1-4 on four viruses is shown in Table 1. The cell control group shows “-” under all virus types, which indicates that the cells not contacted with viruses grow well and no cell pathogenic effect occurs. The virus control group shows “++++” against respiratory syncytial virus, influenza A virus, influenza B virus, and rhinovirus, which indicates that the cells are severely infected in the presence of only viruses, and more than 75% of the cells are pathogenic, verifying the effectiveness of the virus-infected cell model in the experiment. Ribavirin has a certain degree of inhibition on the four viruses (partially showing “+” and partially showing “-”), which indicates that ribavirin as a commonly used antiviral drug has the expected antiviral effect on the four viruses under the experimental conditions, and can be used as a reference standard for the antiviral effect of essential oils. Atractylodes lancea essential oil and saposhnikovia divaricata essential oil show inhibition effect (showing “+++”) on the four viruses, which indicates that atractylodes lancea essential oil and saposhnikovia divaricata essential oil have antiviral effect. Compound essential oils 1-4 show inhibition effect (showing “+++” to “-”) on the four viruses, and the inhibition effect of different formulations of compound essential oils on the four viruses is different, and some compound essential oils show stronger virus inhibition effect.

[0082] Table 2 cell CPE

[0083]

[0084] Test Example 2 Carbon Particle Clearance Phagocytosis Experiment of Essential Oil Composition of the Invention in Mice

[0085] 1. Test substance

[0086] Compound essential oil group 1: saposhnikovia divaricata essential oil 1 g, atractylodes lancea essential oil 1 g.

[0087] Compound essential oil group 2: saposhnikovia divaricata essential oil 1 g, atractylodes lancea essential oil 1 g, atractylodes chinensis essential oil 1 g.

[0088] Compound essential oil group 3: saposhnikovia divaricata essential oil 1 g, atractylodes lancea essential oil 1 g, atractylodes chinensis essential oil 1 g, lonicera japonica essential oil 2 g, mentha essential oil 2 g, perilla essential oil 1 g.

[0089] Compound essential oil group 4: saposhnikovia divaricata essential oil 1 g, atractylodes lancea essential oil 1 g, atractylodes chinensis essential oil 1 g, lonicera japonica essential oil 2 g, mentha essential oil 2 g, perilla essential oil 1 g, eucalyptus (eucalyptus leaf) essential oil 2 g.

[0090] 2. Experimental grouping

[0091] Take 72 Kunming mice, half male and half female, and randomly divide them into 9 groups: normal control group, model control group, levamisole group, saposhnikovia divaricata essential oil group, atractylodes lancea essential oil group, compound essential oil group 1, compound essential oil group 2, compound essential oil group 3, and compound essential oil group 4, each containing 8 mice.

[0092] 3. Modeling and administration

[0093] The normal control group was injected with 10 ml / kg of physiological saline, and the other groups were injected with 50 mg / kg of cyclophosphamide intraperitoneally for 2 consecutive days. From the 3rd day, the injection was performed every other day, and the injection was continued until the 10th day. From the 1st day of modeling, the normal control group, the model control group, and the essential oil group were subjected to aerosol aromatherapy for 15 minutes, 3 times a day, with an interval of 6 hours each time. The normal control group and the model control group were treated with 25 ml of physiological saline, and the essential oil group was treated with essential oil added to 25 ml of physiological saline. The animal aromatherapy room had a space volume of about 50 L (52 cm x 38 cm x 25 cm), and the administration dose was 0.17 g / (kg·d). The levamisole group was given 50 mg / (kg·d) of levamisole by gavage. The administration was continued for 10 days. On the 11th day in the afternoon, the macrophage phagocytosis carbon particle clearance test was performed: 0.1 ml / 10 g of ink: physiological saline (3:1) mixed solution was injected into the tail vein of each mouse. At 2 minutes (t1) and 10 minutes (t2) after the ink injection, 20 μl of blood was taken from the eye socket, 2 ml of 1% Na2CO3 solution was added, it was shaken well, and the OD value was measured at a wavelength of 680 nm. The OD values were OD1 and OD2, respectively. After 10 minutes, the mice were sacrificed, the liver and spleen were dissected, weighed, and the carbon clearance index K and phagocytosis index a were calculated.

[0094] K = (lgOD1-lgOD2) / (t2-t1)

[0095] a = K 1 / 3 · [body weight / (liver weight + spleen weight)]

[0096] 4. Experimental results and conclusions

[0097] The results of the effect of essential oils on the phagocytic function of liver and spleen macrophages in immunosuppressed mice are shown in Table 3. Compared with the normal control group, the carbon clearance index K and phagocytosis index a of the model control group were significantly reduced (P<0.01), and the mice showed an immunosuppressed state, and the phagocytic function of macrophages was significantly inhibited, indicating that the cyclophosphamide modeling was successful. Compared with the model control group, the carbon clearance index K and phagocytosis index a of the levamisole group and the essential oil group were significantly increased (P<0.05), indicating that levamisole and essential oils both have the effect of enhancing the phagocytic function of macrophages in immunosuppressed mice, and there is a certain difference between different compound essential oil groups. Baizhu essential oil, Fangfeng essential oil, and compound essential oil all have the effect of resisting cyclophosphamide-induced immunosuppression, can enhance the phagocytic function of liver and spleen macrophages in immunosuppressed mice, and thus improve the cellular immune capacity of the body.

[0098] Table 3 Effect of essential oils on the phagocytic function of liver and spleen macrophages in immunosuppressed mice

[0099]

[0100] Note: compared with the normal control group, * P<0.05, ** P<0.01; compared with the model control group, # P<0.05, ## P<0.01; compared with the levamisole group, ▲ P<0.05, ▲▲ P<0.01.

[0101] Effect of essential oil composition of the application on allergic rhinitis guinea pigs

[0102] An allergic rhinitis (AR) guinea pig model was established using ovalbumin (OVA); the severity of AR symptoms was recorded using the integral method; and the levels of IL-4, IL-12, and IFN-γ in the serum of guinea pigs in each group were detected using the ELISA method.

[0103] 1 Test substance

[0104] Compound essential oil group 1: 1 g of Saposhnikovia divaricata essential oil and 1 g of Atractylodes lancea essential oil.

[0105] Compound essential oil group 2: 1 g of Saposhnikovia divaricata essential oil, 1 g of Atractylodes lancea essential oil, and 1 g of Atractylodes lancea essential oil.

[0106] Compound essential oil group 3: 1 g of Saposhnikovia divaricata essential oil, 1 g of Atractylodes lancea essential oil, 1 g of Atractylodes lancea essential oil, 2 g of Magnolia denudata essential oil, 2 g of Mentha haplocalyx essential oil, and 1 g of Perilla frutescens essential oil.

[0107] Compound essential oil group 4: 1 g of Saposhnikovia divaricata essential oil, 1 g of Atractylodes lancea essential oil, 1 g of Atractylodes lancea essential oil, 2 g of Magnolia denudata essential oil, 2 g of Mentha haplocalyx essential oil, 1 g of Perilla frutescens essential oil, and 2 g of Eucalyptus essential oil.

[0108] 2 Experimental grouping

[0109] Ninety British breed mixed color guinea pigs, half male and half female, were randomly divided into 9 groups using the random number method: a blank group, a model group, a Saposhnikovia divaricata essential oil group, an Atractylodes lancea essential oil group, a compound essential oil group 1, a compound essential oil group 2, a compound essential oil group 3, a compound essential oil group 4, and a mometasone furoate group, 10 guinea pigs in each group.

[0110] 3 Establishment of an AR guinea pig model and administration

[0111] AR guinea pigs were modeled, except for the blank group, the rest of the guinea pigs were injected intraperitoneally with 0.3 mg OVA (ovalbumin) + 30 mg Al(OH)3+ 0.9% NaCl liquid 1 ml suspension every other day, a total of 7 injections; on the 2nd day after intraperitoneal injection, the guinea pigs were anesthetized with inhaled anesthetic isoflurane, and then 20 μl of 5% OVA + 0.9% NaCl solution was dropped into the nostrils of the guinea pigs to attack the local antigen, twice a day at fixed time in the morning and evening, for 7 consecutive days. The behaviors of scratching the nose, sneezing and running nose of the guinea pigs were observed within 30 minutes after the last challenge, and scored. The total score was more than 5, which was considered to be successful modeling, and the scoring criteria were as follows.

[0112] Table 4 Scoring criteria for guinea pig AR model

[0113]

[0114] After successful modeling, the guinea pigs in the blank group, model group and essential oil group were subjected to atomization aromatherapy for 15 minutes, among which the blank group and model group were 25 ml water, and the essential oil group was 25 ml water with essential oil. The animal aromatherapy room had a space volume of about 50 L (52 cm x 38 cm x 25 cm), and the dose was 0.10 g / kg. The mometasone furoate group was treated with a micro-syringe to drop 10 μl of mometasone furoate nasal spray into the nostrils of the guinea pigs, and the treatment was continued for 14 days. At the same time, OVA was dropped into the nostrils every other day to maintain the allergic state.

[0115] 4 Symptom score

[0116] After the last administration for 30 minutes, OVA was dropped into the nostrils for challenge, and the behaviors of scratching the nose, sneezing and running nose of the guinea pigs were observed within 30 minutes, and the degree of the above symptoms was recorded by integral method, and compared with the symptom score before administration.

[0117] 5 ELISA method was used to detect the expression levels of IL-4, IL-12 and IFN-γ in the serum of guinea pigs in each group

[0118] After the last challenge for 24 hours, the guinea pigs were anesthetized, and blood was taken from the abdominal aorta. The serum was separated, and the expression of immune cytokines IL-4, IL-12 and IFN-γ in the serum of guinea pigs in each group was detected by ELISA method. The operation was carried out according to the instructions of the kit.

[0119] 6 Experimental results and conclusions

[0120] The symptom scores of guinea pigs in the AR guinea pig experiment are shown in Table 5. Compared with the blank group, the behavior scores of guinea pigs in the model group increased significantly, and obvious AR symptoms appeared, indicating that the modeling was successful. Compared with the model group, the behavior scores of guinea pigs in the single essential oil group, the compound essential oil group and the mometasone furoate group decreased significantly after treatment (P<0.01). Compared with the mometasone furoate group, there was no significant difference between compound essential oil 3 and compound essential oil 4, and the rest of the compound essential oil groups and the single essential oil group had significant differences (P<0.05). The results showed that the essential oil of Atractylodes macrocephala and the essential oil of Saposhnikovia divaricata could improve the behavior symptoms of AR guinea pigs to varying degrees, but compound essential oil 3 and compound essential oil 4 had stronger improvement effect on AR symptoms of guinea pigs, indicating that the compatibility of essential oils could have synergistic effect.

[0121] Table 5 Symptom scores of guinea pigs

[0122]

[0123] Note: Compared with the blank group, * P<0.05, ** P<0.01; compared with the model group, # P<0.05, ## P<0.01; compared with the mometasone furoate group, ▲ P<0.05, ▲▲ P<0.01.

[0124] The levels of IL-4, IL-12, IFN-γ and other factors in the serum of guinea pigs are shown in Table 6. Compared with the blank group, the expression of IL-4 and IL-12 in the model group increased, and the expression of IFN-γ decreased (P<0.01); compared with the model group, the essential oil of Saposhnikovia divaricata, the mometasone furoate group and the compound essential oil group could significantly reduce the expression of IL-4 and IL-12 in the serum of guinea pigs (P<0.05), and the essential oil of Atractylodes macrocephala and the compound essential oil group could increase the expression of IFN-γ (P<0.05). Compared with the mometasone furoate group, there was no significant difference in IL-12 in the serum of guinea pigs in compound essential oil 3 and compound essential oil 4, and there was no significant difference in IFN-γ in the serum of guinea pigs in compound essential oil 4. The results showed that the essential oil of Atractylodes macrocephala and the essential oil of Saposhnikovia divaricata could regulate IL-4, IL-12, IFN-γ and other factors in the serum of AR guinea pigs to varying degrees, but compound essential oil 3 and compound essential oil 4 had stronger inhibitory effect on IL-4 and IL-12 in the serum of guinea pigs, and stronger promoting effect on IFN-γ, indicating that the compatibility of essential oils could have synergistic effect.

[0125] Table 6 Levels of IL-4, IL-12, IFN-γ and other factors in the serum of guinea pigs detected by ELISA

[0126]

[0127] Note: Compared with the blank group,* P<0.05, ** P<0.01; compared with the model group, # P<0.05, ## P<0.01; compared with the mometasone furoate group, ▲ P<0.05, ▲▲ P<0.01.

[0128] Clinical study of essential oil composition of the application

[0129] 1. Treatment or improvement of upper respiratory tract infection

[0130] 1.1 Select 60 cases of upper respiratory tract infection patients from a hospital in Yibin City from August 2023 to August 2024.

[0131] 1.2 Diagnostic criteria

[0132] The following criteria are developed in reference to the relevant contents of "Guidelines for Diagnosis and Treatment of Common Diseases in Internal Medicine of Traditional Chinese Medicine" (published by Chinese Society of Traditional Chinese Medicine, 2008 edition) and "Guidelines for Clinical Research of New Drugs of Traditional Chinese Medicine" (2002 edition):

[0133] (1) Local symptoms are dominant, and systemic symptoms may or may not be obvious; local symptoms include sneezing, nasal congestion, runny nose, and sometimes cough, sore throat, hoarseness, and tearing; systemic symptoms include chills, fever, general discomfort, headache, dizziness, and soreness in the limbs, waist, and back;

[0134] 1.3 Inclusion criteria

[0135] (1) Meet the above criteria;

[0136] (2) Age between 18-65 years old (including 18 years old and 65 years old), gender unrestricted;

[0137] (3) Volunteers participating in this research, able to accept relevant examinations and treatments, and sign the informed consent form.

[0138] 1.4 Exclusion criteria

[0139] (1) Body temperature (axillary) > 38.5℃;

[0140] (2) Patients with chronic bronchitis, chronic obstructive pulmonary disease, emphysema, and pulmonary heart disease;

[0141] (3) Patients with severe heart, brain, and hematopoietic system primary diseases, severe liver and kidney function impairment, malignant tumors, and patients with pulmonary infection and mental illness;

[0142] (4) Patients with allergic constitution or allergy to multiple drugs, or with a history of allergy to the components of the drugs used in this trial;

[0143] (5) Pregnant or lactating women;

[0144] (6) Patients who have used other drugs for treating the disease after the onset;

[0145] (7) Patients who do not take the drug as prescribed, or whose data is incomplete to affect the determination of efficacy.

[0146] 1.5 Treatment regimen

[0147] According to the random number table method, 60 patients with upper respiratory tract infection were divided into control group and treatment group. Compound essential oil 4 was diluted with base oil to a concentration of 10% massage oil. Control group: symptomatic treatment (such as fever treatment, cough and sputum, fluid replacement therapy, and antibiotic treatment in the case of bacterial infection); Treatment group: give patients massage oil, rub the temples, welcome fragrance, wind pool, and curve pool for 3 minutes, the dosage is 0.5ml each time, twice a day. Continuous treatment for 7 days.

[0148] 1.6 Efficacy indicators

[0149] Table 7 Upper respiratory tract infection TCM symptom score table

[0150]

[0151]

[0152] The main symptoms and secondary symptoms of upper respiratory tract infection patients are as follows: mild: ≤10 points, moderate: 11-20 points, severe: ≥20 points

[0153] Efficacy index = (pre-treatment score - post-treatment score) / pre-treatment score x 100%

[0154] Treatment efficiency = [clinical cure cases + effective cases + effective cases] / total cases] x 100%

[0155] (1) Cure: clinical symptoms disappear or basically disappear, and syndrome score reduction ≥95%.

[0156] (2) Effective: clinical symptoms improved significantly, and syndrome score reduction ≥70%.

[0157] (3) Effective: clinical symptoms improved partially, and syndrome score reduction ≥30%.

[0158] (4) Ineffective: clinical symptoms did not improve significantly or even worsened, and syndrome score reduction less than 30%.

[0159] Record the TCM symptom scores of patients before treatment, and on the third day, fifth day and seventh day of treatment.

[0160] 1.7 Safety evaluation

[0161] The incidence of adverse reactions during treatment was statistically compared between the two groups.

[0162] 1.8 Results and Conclusions

[0163] (1) Comparison of TCM symptom scores before and after treatment in patients of the two groups

[0164] The TCM symptom scores of patients before and after treatment are shown in Table 8. Compared with before treatment, both the treatment group and the control group can significantly alleviate the patient's condition. Compared with the control group, the symptoms of patients in the treatment group were significantly improved on the third day, the fifth day, and the seventh day during treatment. The results show that the use of compound essential oil can quickly improve the clinical symptoms of patients and continuously alleviate the patient's condition in the later stage of the disease.

[0165] Table 8 Comparison of TCM symptom scores during treatment in patients of the two groups

[0166]

[0167] Note: Compared with the control group, * P<0.05, ** P<0.01; compared with before treatment, # P<0.05, ## P<0.01;

[0168] (2) Comparison of clinical efficacy in patients of the two groups

[0169] The clinical efficacy of patients is shown in Table 9. The results show that compound essential oil can effectively treat upper respiratory tract infection.

[0170] Table 9 Comparison of clinical efficacy in patients of the two groups

[0171]

[0172] (3) Safety evaluation

[0173] During the treatment process, all patients had no adverse reactions reported.

[0174] 2 Treatment or improvement of rhinitis

[0175] 2.1 Eighty patients with rhinitis who visited the ENT department of a hospital in Yibin City from August 2023 to August 2024 were selected.

[0176] 2.2 Diagnosis criteria

[0177] Refer to the diagnostic criteria and symptom efficacy score standard formulated by the Society of Otolaryngology Head and Neck Surgery of the Chinese Medical Association, China Allergic Rhinitis Diagnosis and Treatment Guidelines (2022, revised edition), and refer to the Common Diseases Diagnosis and Treatment Guidelines of TCM Otolaryngology (China Press of Chinese Medicine, published in 2012), Diagnosis and Treatment Criteria of TCM Diseases (China Medical Science and Technology Press, published in 2012), and the relevant diagnostic criteria in the Guiding Principles for Clinical Research of New Drugs for Rhinitis, to develop the following standards:

[0178] (1) Symptoms: 2 or more of sneezing, clear watery nasal discharge, nasal itching and nasal congestion; symptoms persist or accumulate for more than 1 hour per day, accompanied by respiratory symptoms (pharyngitis, cough, wheezing, etc.) and eye symptoms (including eye itching, tearing, redness and burning sensation, etc.); fever, fever; dry throat, dry mouth; olfactory abnormalities such as reduction, disappearance or phantom smell; other concomitant disease symptoms such as nosebleed.

[0179] (2) Signs: Common signs of pale and edematous nasal mucosa, and watery nasal discharge.

[0180] 2.3 Inclusion Criteria

[0181] (1) Meet the above diagnostic criteria;

[0182] (2) Age between 18 and 60 years old (including 18 and 60 years old), gender not limited;

[0183] (3) Volunteers participating in this research, can accept relevant examinations and treatment, and sign the informed consent form.

[0184] 2.4 Exclusion Criteria

[0185] (1) Allergic to the study drug;

[0186] (2) With chronic rhinosinusitis, nasal polyps or other nasal diseases or nasal surgery;

[0187] (3) Combined with other serious cardiovascular, liver and hematopoietic system diseases or malignant tumors, patients with mental illness and Alzheimer's disease;

[0188] (4) Lactating women, pregnant or pregnant women;

[0189] (5) Received related drug treatment or is receiving desensitization treatment within 1 week of the onset of rhinitis.

[0190] 2.5 Treatment Plan

[0191] According to the random number table method, 60 patients with rhinitis were divided into control group and treatment group. Compound essential oil 4 was diluted with base oil to a concentration of 10% massage oil. The control group was given mometasone furoate nasal spray, 2 sprays per nostril, twice a day, for 14 days of continuous treatment. The treatment group was combined with massage oil on the basis of the control group. Massage oil was applied to both sides of the alae nasi and the lower part of the nostrils. The dosage was 0.5 ml each time, twice a day. The acupoints were rubbed for 3 minutes, including yintang, zuanzhu, bitong, and yingxiang. The nose root was pinched and rubbed 60 times on both sides of the alae nasi. Continuous treatment for 14 days.

[0192] 2.6 Rhinitis symptom score

[0193] The patients' nasal congestion, runny nose, nasal itching, and sneezing were scored before and after treatment. The severity of the symptoms was scored from 0 to 3, with 0 being asymptomatic, 1 being mild symptoms (mild symptoms, easy to tolerate), 2 being moderate symptoms (obvious symptoms, annoying but tolerable), and 3 being severe symptoms (symptoms cannot be tolerated, affecting daily life and / or sleep). The efficacy index = [(pre-treatment score - post-treatment score) / pre-treatment score] x 100%. Marked effect: efficacy index ≥ 60%; effective: 20% ≤ efficacy index < 60%; ineffective: efficacy index < 20%. Total effective rate = (number of effective cases + number of effective cases) / total number of cases x 100%

[0194] 2.7 Quality of life evaluation

[0195] Before and after treatment, the Rhinitis Quality of Life Questionnaire (RQLQ) was used for evaluation (Annex 1). RQLQ contains 28 questions, divided into 7 areas: daily activities, sleep, non-nasal and eye symptoms, practical problems, nasal symptoms, eye symptoms, activity, and mood. Each item is scored according to 0-6, with 0 being no distress, 1 being almost no distress, 2 being some distress, 3 being moderate distress, 4 being very distress, 5 being very distress, and 6 being extreme distress. The higher the score, the lower the quality of life.

[0196] 2.8 Safety evaluation

[0197] The incidence of adverse reactions during treatment was statistically analyzed.

[0198] 2.9 Results and conclusions

[0199] (1) Clinical efficacy

[0200] 30 patients with rhinitis using mometasone furoate nasal spray and compound essential oil after 14 days, 14 cases reached the effective, effective in 13 cases, only 3 cases, the total effective rate was 90%, and 30 patients with rhinitis using mometasone furoate nasal spray after 14 days, 10 cases reached the effective, effective in 16 cases, 4 cases, the total effective rate was 86.67%. The results showed that the compound essential oil combined with mometasone furoate nasal spray had good treatment or improvement effect on rhinitis.

[0201] Table 10 Treatment effect of compound essential oil on rhinitis

[0202]

[0203] (2) Four-point method score and RQLQ score

[0204] After treatment, the four-point method score, RQLQ total score and sleep score of the patients were lower than those before treatment (P<0.05), and the compound essential oil combined with mometasone furoate nasal spray improved the symptoms of rhinitis, life level and sleep quality of the patients.

[0205] Table 11 Comparison of four-point method score and RQLQ score before and after treatment

[0206]

[0207]

[0208] Note: Compared with the control group, * P<0.05, ** P<0.01; compared with before treatment, # P<0.05, ## P<0.01;

[0209] (3) Safety evaluation

[0210] During the treatment, all patients had no adverse reactions reported.

[0211]

[0212] Activities

[0213] We hope you can recall the situation of your nasal / ocular symptoms causing trouble in your life, and we want to know what you do but are limited by your nasal / ocular symptoms. The limitations you suffer mean that you do less, or do it less well, or it is not as enjoyable as usual. These activities should be something you usually do, or are important to your daily life, and you do them regularly throughout the study.

[0214] Below is a list of activities that you may have been limited in due to your nose / eye symptoms. We hope this helps you identify your 3 main activities that you have been limited in over the past 7 days due to your nose / eye symptoms.

[0215]

[0216] Write down your 3 main activities in the underlined boxes, then use a "√" in the boxes to indicate how much you have been bothered by your nose / eye symptoms in the past 7 days for that activity.

[0217]

[0218] Sleep

[0219] How much have you been bothered by the following sleep problems in the past 7 days due to your nose / eye symptoms?

[0220]

[0221] Non-nose / eye symptoms

[0222] How much have you been bothered by the following problems in the past 7 days due to your nose / eye symptoms?

[0223]

[0224]

[0225] Practical problems

[0226] How much have you been bothered by the following problems in the past 7 days due to your nose / eye symptoms?

[0227]

[0228] Nose symptoms

[0229] How much have you been bothered by the following problems in the past 7 days?

[0230]

[0231]

[0232] Eye symptoms

[0233] How much have you been bothered by the following problems in the past 7 days?

[0234]

[0235] Emotions

[0236] In the past 7 days, how often have you been bothered by emotional problems because of your nasal / eye symptoms?

[0237]

[0238] Please fill in every option, no missing, thank you!

Claims

1. The invention relates to a method for preparing a medicament for preventing and / or treating upper respiratory tract infection or rhinitis by combining siler essential oil and atractylodes macrocephala essential oil, wherein the weight ratio of siler essential oil and atractylodes macrocephala essential oil is: 0.5-1.5 parts of siler essential oil and 0.5-1.5 parts of atractylodes macrocephala essential oil; Preferably, the weight ratio of siler essential oil and atractylodes macrocephala essential oil is: 1 part of Saposhnikovia divaricata essential oil and 1 part of Atractylodes macrocephala essential oil.

2. The use according to claim 1, characterized in that: The medicine is a medicine for preventing or / treating allergic rhinitis.

3. An essential oil composition for preventing and / or treating upper respiratory tract infection or rhinitis, characterized in that: It is composed of the following raw materials in the following weight ratios: 0.5-1.5 parts of siler essential oil and 0.5-1.5 parts of atractylodes macrocephala essential oil; Preferably, it is composed of the following raw materials in the following weight ratio: 1 part of Saposhnikovia divaricata essential oil and 1 part of Atractylodes macrocephala essential oil.

4. The essential oil composition for preventing and / or treating upper respiratory tract infection or rhinitis according to claim 3, characterized in that: The raw materials also contain atractylodes essential oil, and the weight ratio of the raw materials is: 0.5-1.5 parts of siler essential oil, 0.5-1.5 parts of atractylodes essential oil, 0.5-1.5 parts of atractylodes essential oil; Preferably, the weight ratio of the raw materials is: 1 part of fangfeng essential oil, 1 part of atractylodes essential oil, and 1 part of atractylodes essential oil.

5. The essential oil composition for preventing and / or treating upper respiratory tract infection or rhinitis according to claim 4, characterized in that: The raw materials further contain magnolia essential oil, peppermint essential oil, and perilla essential oil, and the weight ratio of the raw materials is: 0.5-1.5 parts of siler essential oil, 0.5-1.5 parts of atractylodes essential oil, 0.5-1.5 parts of atractylodes essential oil, 1-3 parts of magnolia essential oil, 1-3 parts of peppermint essential oil, and 0.5-1.5 parts of perilla essential oil; Preferably, the weight ratio of the raw materials is: 1 part of fangfeng essential oil, 1 part of atractylodes essential oil, 1 part of atractylodes essential oil, 2 parts of magnolia essential oil, 2 parts of peppermint essential oil, and 1 part of perilla essential oil.

6. The essential oil composition for preventing and / or treating upper respiratory tract infection or rhinitis according to claim 5, characterized in that: The raw materials further contain eucalyptus essential oil, or wintersweet essential oil, or camphor essential oil, or lemongrass essential oil, and the weight ratio of the raw materials is: 0.5-1.5 parts of siler essential oil, 0.5-1.5 parts of atractylodes essential oil, 0.5-1.5 parts of atractylodes essential oil, 1-3 parts of magnolia essential oil, 1-3 parts of peppermint essential oil, 0.5-1.5 parts of perilla essential oil, 0.5-3 parts of eucalyptus essential oil, or wintersweet essential oil, or camphor essential oil, or lemongrass essential oil; Preferably, the weight ratio of the raw materials is: 1 part of fangfeng essential oil, 1 part of atractylodes essential oil, 1 part of atractylodes essential oil, 2 parts of magnolia essential oil, 2 parts of peppermint essential oil, 1 part of perilla essential oil, and 2 parts of eucalyptus essential oil.

7. Use of the essential oil composition according to any one of claims 3 to 6 in the preparation of an external-use medicament or preparation for preventing and / or treating upper respiratory tract infection or rhinitis.

8. The use according to claim 7, characterized in that: The rhinitis is allergic rhinitis.

9. The use according to claim 8 or 9, characterized in that: The preparation of the external medicine is an inhalant, an atomizer, or an acupuncture point administration agent.

10. The use according to claim 9, characterized in that: The acupoint medication is administered at the temple, Yingxiang acupoint, Fengchi acupoint and Quchi acupoint.

Images